In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 adopted for its implementation, as amended and supplemented, the Competition Council makes available to the public the ‘operation summary’ below, containing the information provided by the parties.<\/p>\n
This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation.<\/p>\n
The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 adopted for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented.<\/p>\n
Names of companies and individuals concerned:<\/strong><\/p>\n Nature of the operation<\/strong><\/p>\n Economic sector concerned:<\/strong><\/p>\n Deadline for interested third parties to submit their observations:<\/strong><\/p>\n NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES<\/strong><\/p>\n The Competition Council received notification of an economic concentration operation concerning the indirect exclusive takeover of the company ‘Biogaran SAS’ by the company ‘BC Partners LLP’ through the acquisition of all of its share capital and associated voting rights.<\/p>\n ‘Bastille Bidco SAS’ is a simplified joint-stock company with its registered office at 182 B Boulevard Pereire, 75017 Paris, France, with a unique identification number of 989 317 334 RCS Paris. ‘Bastille Bidco SAS’ is an entity owned by a fund advised by ‘BC Partners’. ‘BC Partners’ is an international asset management company based in London whose exclusive activity is to provide advisory services. Funds advised by ‘BC Partners’ are financial investors.<\/p>\n ‘Biogaran SAS’ is a simplified joint-stock company, with its registered office at 15 bd Charles de Gaulle, 92700 Colombes, France, and with an identification number of 405 113 598 RCS Nanterre. ‘Biogaran SAS’ is engaged in the promotion, distribution, marketing, and sale of generic drugs, biosimilar drugs, a small range of over-the-counter drugs, dietary supplements, cosmetics, and medical devices for daily ailments, care, and well-being.<\/p>\n <\/p>\n Done in Rabat, September 11, 2025<\/p>\n","protected":false},"excerpt":{"rendered":" In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 adopted for its implementation, as amended and supplemented, the Competition Council makes available to the public the ‘operation summary’ below, containing the information provided by the parties. This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation. The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 adopted for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented. Names of companies and individuals concerned: The direct acquirer: The company ‘Bastille Bidco SAS’; The indirect acquirer: The company ‘BC Partners LLP’; The target: The company ‘Biogaran SAS’. Nature of the operation Indirect exclusive takeover. Economic sector concerned: Pharmaceutical sector. Deadline for interested third parties to submit their observations: 10 days from the date of publication of this press release, i.e. September 22, 2025. NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES The Competition Council received notification of an economic concentration operation concerning the indirect exclusive takeover of the company ‘Biogaran SAS’ by the company ‘BC Partners LLP’ through the acquisition of all of its share capital and associated voting rights. ‘Bastille Bidco SAS’ is a simplified joint-stock company with its registered office at 182 B Boulevard Pereire, 75017 Paris, France, with a unique identification number of 989 317 334 RCS Paris. ‘Bastille Bidco SAS’ is an entity owned by a fund advised by ‘BC Partners’. ‘BC Partners’ is an international asset management company based in London whose exclusive activity is to provide advisory services. Funds advised by ‘BC Partners’ are financial investors. ‘Biogaran SAS’ is a simplified joint-stock company, with its registered office at 15 bd Charles de Gaulle, 92700 Colombes, France, and with an identification number of 405 113 598 RCS Nanterre. ‘Biogaran SAS’ is engaged in the promotion, distribution, marketing, and sale of generic drugs, biosimilar drugs, a small range of over-the-counter drugs, dietary supplements, cosmetics, and medical devices for daily ailments, care, and well-being. Done in Rabat, September 11, 2025<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[352],"tags":[],"class_list":["post-39070","post","type-post","status-publish","format-standard","hentry","category-press-releases"],"acf":[],"yoast_head":"\n\n
\n
\n
\n